Answers are grounded in this paper and cite their sources.
Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus immunoprophylaxis is recommended, we examined adherence in infants enrolled during healthcare visits for acute respiratory illness in 3 U.S. counties from 2001 to 2007. Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33% to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not meet eligibility criteria.
No takes yet. Share an insight, caveat, or question.
Carroll et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: